Short Interest in Teva Pharmaceutical Industries Ltd (TEVA) Declines By 13.6%
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 80,161,471 shares, a decrease of 13.6% from the November 15th total of 92,803,223 shares. Based on an average daily volume of 24,072,035 shares, the days-to-cover ratio is currently 3.3 days.
Teva Pharmaceutical Industries (TEVA) opened at $17.45 on Thursday. The company has a market cap of $18,816.32, a price-to-earnings ratio of 4.28 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $38.31.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were given a dividend of $0.085 per share. The ex-dividend date was Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 1.95%. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.
Several research firms recently commented on TEVA. UBS set a $20.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday. Piper Jaffray Companies set a $16.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 14th. Royal Bank of Canada set a $13.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Friday, December 15th. Cantor Fitzgerald set a $10.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 14th. Finally, BTIG Research upped their price target on shares of Teva Pharmaceutical Industries to $20.00 in a research report on Friday, December 15th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $20.68.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/21/short-interest-in-teva-pharmaceutical-industries-ltd-teva-declines-by-13-6.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.